BOARD OF DIRECTORS



Pr Sylvie DELANIAN President



Dr Pierre-François PRADAT Vice-President



Roselyne NICOLAS General Secretary



Benoît BRUET Treasurer



Jean-Pierre BRIOT External Relations

SCIENTIFIC COUNCIL



Dr Pierre-Francois PRADAT Pdt - Neurologist



Pr Sylvie DELANIAN V-Pdt - Oncology Radiotherapy



Vascular Radiologist



Dr Sameh AWAD Pr Céline BOURGIER Oncology Radiotherapy



Dr Cécile CHÂTEL Odontology



Dr Alexandra FOURCADE Ministère de la Santé



Pr Mehdi KAROUI Visceral and Digestive Surgery



Jean-Louis LEFAIX Docteur ès Sciences former Researcher



Dermatology



Lymphology



Dr Gwendoline SEBILLE Dr Stéphane VIGNES Pr Marie-Catherine VOZENIN Docteur ès Sciences Radio-Oncology

REGIONAL AND INTERNATIONAL DELEGATIONS



Hugues LELOUP Auvergne - Rhône Alpes



Carole NAVICET Centre - Val de Loire



Isabel KELLER Grand Est



Jean-Pierre BRIOT lle de France



Robert PALLUAULT Nouvelle Aquitaine



Occitanie



Chantal GONZALEZ PACA and Corsica



Jean-Marie CARIAGE Switzerland

BOARD

President: Pr Sylvie DELANIAN, Vice-President: Dr Pierre-François PRADAT, General Secretary: Roselyne NICOLAS, Treasurer: Benoît BRUET, External Relation Manager: Jean-Pierre BRIOT, Delegations: Switzerland: Jean-Marie CARIAGE, Occitanie: Hans CARL.



www.arser.org ecrire.arser@gmail.com



To take into account the after effects of radiotherapy



Contribute to research Raising awareness among public opinion and public authorities Promote exchanges with other associations Provide support to patients and their families

www.arser.org



ARSER - 70 bd de l'Hôpital - 75013 PARIS - FRANCE ecrire.arser@gmail.com

WHY ARSER?

ARSER's main objective is to develop research on the after effects of radiotherapy and, to achieve this, to raise funds.

Its purpose is not legal claims: ARSER does not intend to bring together patients considering that they are «victims» of radiotherapy. ARSER wants to inform patients and doctors about the progress of research on the after effects of radiotherapy and finance it.

Doctor Sylvie Delanian is among the very first doctors in the world to be concerned, as a radiotherapist, about the after effects of radiotherapy and to have provided answers, in particular, relative to treatments already in use for more than 15 years.

She led with **Jean-Louis Lefaix**, ex-researcher at the CEA, then with **Doctor Pierre-François Pradat**, neurologist, research to better understand the mechanisms and **to develop new treatments that may reduce these consequences**.

Many patients, long cured of their cancer, known as «long survivors» and out of the medical circuit, are often unaware that the badly systemised symptoms from which they suffer are after effects from radiotherapy.

WHAT IS RADIOTHERAPY?

Radiotherapy is a tool (local, such as surgery), essential to treat the cancer. It is made with ionizing radiation and delivers a given energy to a given tissue, in order to kill the cells in the tumour.



(1)


WHAT ARE THE COMPLICATIONS RELATED TO RADIOTHERAPY?

Generally, patients are followed regularly for five years. We monitor a possible cancer relapse or immediate complications from oncology treatments. Beyond that, the patients, considered cured, are rarely followed and yet they can be confronted with more or less serious pathologies.

ARE THESE AFTER EFFECTS IRREVERSIBLE?

A dogma is widespread among doctors, in the limited knowledge so far taught, according to which radiation-related injuries (especially neurological) are irreversible.

This dogma is false since, for more than 15 years, new treatments have appeared, which can reverse the side effects.



WHAT MEANS FOR RESEARCH?



France has capabilities, researchers - in particular young researchers - but unfortunately no budget for this activity.

Also, this question is too often considered as an «after-sale service» and not «noble» enough.

MEMBERSHIP



I have read the objectives of ARSER and I would like to join it.

Surname:
First name:
Address:
Postal code:
City:
E-mail: (ARSER members are informed by email!)
Phone:
Mobile phone:
• The amount of the annual SUBSCRIPTION FEE is €35. In return for your subscription fee, you will receive a TAX RECEIPT, enabling you to deduct from your French income tax of the following year, 66% of the amount contributed to the ARSER. After tax reduction, the €35 contribution will cost only €11.90.
 A complementary DONATION intended to directly help MEDICAL RESEARCH can also be made and it also benefits the tax deduction.
I write my cheque to the order of ARSER for: $\ensuremath{\varepsilon}$
deductible from my tax, including:
- a Subscription fee of:
- a Donation for research of: €
☐ I accept that my surname, first name, city, postal code, e-mail address appear in the site directory, only accessible to ARSER members.

Form and cheque to be sent to:

Date: Signature:

ARSER
70 boulevard de l'Hôpital
75013 PARIS
FRANCE